3.55 USD
+0.28 (+8.56%)
We assign a fundamental rating of 4 out of 10 to ATHE. ATHE was compared to 525 industry peers in the Biotechnology industry. The financial health of ATHE is average, but there are quite some concerns on its profitability. ATHE is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
- In the past year ATHE has reported negative net income.
- In the past year ATHE has reported a negative cash flow from operations.
- In the past 5 years ATHE always reported negative net income.
- ATHE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -26.39%, ATHE is in the better half of the industry, outperforming 70.29% of the companies in the same industry.
- ATHE's Return On Equity of -28.65% is fine compared to the rest of the industry. ATHE outperforms 77.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.39% | ||
| ROE | -28.65% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ATHE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ATHE does not have a ROIC to compare to the WACC, probably because it is not profitable.
- There is no outstanding debt for ATHE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- ATHE has an Altman-Z score of 8.91. This indicates that ATHE is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 8.91, ATHE belongs to the top of the industry, outperforming 80.38% of the companies in the same industry.
- A Debt/Equity ratio of 0.00 indicates that ATHE is not too dependend on debt financing.
- ATHE has a Debt to Equity ratio (0.00) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.91 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
- ATHE has a Current Ratio of 12.98. This indicates that ATHE is financially healthy and has no problem in meeting its short term obligations.
- ATHE has a Current ratio of 12.98. This is amongst the best in the industry. ATHE outperforms 88.19% of its industry peers.
- A Quick Ratio of 12.98 indicates that ATHE has no problem at all paying its short term obligations.
- With an excellent Quick ratio value of 12.98, ATHE belongs to the best of the industry, outperforming 88.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 12.98 | ||
| Quick Ratio | 12.98 |
3. Growth
3.1 Past
- ATHE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.62%, which is quite impressive.
- The Revenue has grown by 66.28% in the past year. This is a very strong growth!
- ATHE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 92.01% yearly.
EPS 1Y (TTM)59.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.08%
Revenue 1Y (TTM)66.28%
Revenue growth 3Y463.07%
Revenue growth 5Y92.01%
Sales Q2Q%123.33%
3.2 Future
- Based on estimates for the next years, ATHE will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
- ATHE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 180.01% yearly.
EPS Next Y-7643.25%
EPS Next 2Y-779.96%
EPS Next 3Y-326.23%
EPS Next 5Y14.87%
Revenue Next Year1236.54%
Revenue Next 2Y254.11%
Revenue Next 3Y404.68%
Revenue Next 5Y180.01%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ATHE. In the last year negative earnings were reported.
- Also next year ATHE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ATHE's earnings are expected to decrease with -326.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-779.96%
EPS Next 3Y-326.23%
5. Dividend
5.1 Amount
- ATHE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ALTERITY THERAPEUTICS-ADR / ATHE FAQ
What is the fundamental rating for ATHE stock?
ChartMill assigns a fundamental rating of 4 / 10 to ATHE.
What is the valuation status of ALTERITY THERAPEUTICS-ADR (ATHE) stock?
ChartMill assigns a valuation rating of 1 / 10 to ALTERITY THERAPEUTICS-ADR (ATHE). This can be considered as Overvalued.
What is the profitability of ATHE stock?
ALTERITY THERAPEUTICS-ADR (ATHE) has a profitability rating of 1 / 10.
What is the expected EPS growth for ALTERITY THERAPEUTICS-ADR (ATHE) stock?
The Earnings per Share (EPS) of ALTERITY THERAPEUTICS-ADR (ATHE) is expected to decline by -7643.25% in the next year.